Please login to the form below

Not currently logged in
Email:
Password:

Gaucher disease

This page shows the latest Gaucher disease news and features for those working in and with pharma, biotech and healthcare.

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Lilly picks up gene therapy programme in $1bn Prevail Therapeutics acquisition deal

Prevail’s pipeline spans clinical-stage and preclinical neuroscience assets, including lead gene therapies PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD) ... It has also been granted

Latest news

More from news
Approximately 5 fully matching, plus 37 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year. ... BioMarin was awarded a Rare Pediatric Disease PRV when it received approval of Vimizim, a new biological

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Spotlight interview: 15 minutes on patient-centricity in pharma

    Another example was a project we did for Gaucher disease type 1. ... This project involved training nurses on patient activation. The nurses felt they lacked the in-depth connection with their Gaucher disease patients so were unable to make the most of

  • emotive adds to medical team with new Scientific Lead and Associate Medical Writer

    in rare diseases such as Gaucher disease and Cushing’s disease and in hepatitis C. She also has experience in cardiovascular disease, haematology and infectious diseases. ... emotive is an award-winning healthcare communications agency working

  • Making good practice common practice in rare disease

    2016 – Researchers found that people with Gaucher disease ascribed more importance to fatigue than to other disease parameters, while their doctors put greater weight on objective measures of visceral and hematologic ... symptoms. Literature suggests

  • Focus on Rare Diseases

    As pharma becomes more focused on rare disease therapies, Lucid Group recognises that medical education agencies need to respond. ... Lucid’s Rare Disease Business Unit currently works with clients in Fabry disease, Pompe disease, Gaucher disease,

  • Can rare diseases be a viable option for the pharma industry?

    An example of this would be Gaucher’s disease, which has 3 specific sub-types of patients requiring dynamic modeling of the data from patient registries over a 60 year time ... Epiomic Patient Segmentation Database, Metabolic Disorders Category,

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....